Therapeutic
areas in which Haberman Associates principally works include:
- Oncology
- Cardiovascular diseases
- Immune and inflammatory
diseases
- Metabolic diseases
- Central nervous system (CNS) diseases
Examples of the consulting services we have provided
include:
Provided strategic planning support and technology
assessments for large and small biotechnology companies, major research products
companies, and financial services companies. Technology and therapeutic areas
included genomics, proteomics, other drug discovery technologies and applications,
cancer, metabolic diseases, and infectious diseases.
Provided
technology, scientific, and medical inputs as a key member of a team developing
a technology and market-modeling database for a major pharmaceutical company,
to guide resource allocation and new product strategy decisions in the area of
diabetes and obesity drugs.
Assessed early-stage pipeline
drug candidates in diabetes, obesity, and immune and inflammatory diseases for
major pharmaceutical companies, in order to assist the companies in project selection
and resource allocation decisions.
Assisted with initial
planning for a major project to find novel approaches to drug discovery for a
neurodegenerative disease.
Identified and assessed opportunities
in the life sciences for a major Japanese producer of plastics products, including
microfluidics and protein arrays. Further assessed opportunities for the application
of protein arrays to drug discovery and diagnostics, devised market-entry and
partnering strategies, and identified potential North American and European partners.
As a result of our efforts, the client entered into an R&D collaboration with
a leading U.S. developer of protein arrays.
Produced a
proprietary report on recent advances in the area of human adult and embryonic
stem cells for the research products division of a major corporation, and made
recommendations on developing potential commercial opportunities in the stem cell
area. Further assessed opportunities for the same client in leading edge cell
culture technologies that are applicable to stem cell and developmental biology
R&D, drug discovery, in vitro ADME-Tox, and tissue engineering.
Assessed
opportunities in clinical genotyping applications of DNA microarrays for a leading
U.S. corporate R&D laboratory contemplating a spin-off venture.
Produced
a proprietary report on recent developments in glycobiology, in order to assist
a client to identify and assess potential business opportunities in that area.
Analyzed the market potential of a sample of likely early-stage
products and services of a drug delivery start-up firm, in order to assist a technology
incubator to determine the valuation of the company.
Performed
due diligence on emerging and established biotechnology companies and their technologies
and businesses for potential partner companies, as well as corporate funding and
venture capital firms, in order to enable them to make informed partnering and
investment decisions.
